1. Clinical Overview
A fixed-dose combination (FDC) medication used primarily for the symptomatic management of acute and chronic respiratory disorders associated with viscid mucus and bronchospasm. It combines a mucolytic (Ambroxol), a bronchodilator (Terbutaline), and a xanthine derivative (Etofylline) to provide a multi-modal approach to airway clearance and bronchial relaxation. This combination is widely prescribed in India for conditions like COPD and bronchitis.
| Onset | Duration | Bioavailability |
|---|---|---|
| Terbutaline: 5-30 minutes (inhalation), 30-60 minutes (oral). Etofylline: 30-60 minutes. Ambroxol: 30 minutes. | Terbutaline: 3-6 hours. Etofylline: 6-8 hours. Ambroxol: Up to 12 hours. | Ambroxol: ~70-80%. Etofylline: ~80-90%. Terbutaline: ~33-50% (oral). |
2. Mechanism of Action
This combination works synergistically to relieve bronchoconstriction and improve mucus clearance. Terbutaline relaxes bronchial smooth muscle via β2-adrenoceptor stimulation, increasing cAMP. Etofylline, a theophylline derivative, provides bronchodilation through non-selective phosphodiesterase (PDE) inhibition and adenosine receptor antagonism, also increasing cAMP/cGMP. Ambroxol reduces mucus viscosity by stimulating surfactant production in type II pneumocytes and breaking down acid mucopolysaccharide fibers, facilitating expectoration.
3. Indications & Uses
- Symptomatic treatment of Acute Bronchitis
- Symptomatic treatment of Chronic Obstructive Pulmonary Disease (COPD) with tenacious sputum
- Bronchial Asthma with difficulty in expectoration
4. Dosage & Administration
Adult Dosage: One tablet twice daily (every 12 hours). Maximum: Two tablets per day.
Administration: Administer orally after meals with a full glass of water to minimize gastric irritation. Do not crush or chew unless advised. Maintain adequate hydration to aid mucolytic action.
5. Side Effects
Common side effects may include:
- Nausea, Gastric irritation
- Headache
- Mild tremors (especially hand tremor)
- Palpitations
- Nervousness, Restlessness
- Dizziness
6. Drug Interactions
| Drug | Effect | Severity |
|---|---|---|
| Other Beta-2 Agonists (Salbutamol, Formoterol) | Additive cardiovascular and hypokalemic effects; increased risk of side effects. | Major |
| Theophylline/Aminophylline | Increased risk of theophylline (Etofylline metabolite) toxicity (nausea, seizures, arrhythmias). | Major |
| Diuretics (especially loop and thiazide) | Enhanced risk of hypokalemia. Monitor potassium levels. | Major |
| Beta-blockers (e.g., Propranolol) | Mutual antagonism; beta-blockers inhibit bronchodilator effect of Terbutaline. | Major |
| CYP1A2/CYP3A4 Inhibitors (Ciprofloxacin, Erythromycin, Fluvoxamine, Cimetidine) | Increase Etofylline/Theophylline levels, risk of toxicity. | Major |
| CYP1A2 Inducers (Phenobarbital, Phenytoin, Rifampicin, Smoking) | Decrease Etofylline/Theophylline levels, reducing efficacy. | Moderate |
| Digoxin | Possible increased risk of digoxin-induced arrhythmias due to hypokalemia. | Moderate |
| MAOIs and TCAs | Potentiation of cardiovascular effects of Terbutaline. | Major |
7. Patient Counselling
- DO take the tablet after food with plenty of water.
- DO inform your doctor about all other medicines you are taking.
- DO maintain good hydration to help loosen mucus.
- DO report any chest pain, irregular heartbeat, severe headache, or muscle cramps immediately.
- DONT exceed the prescribed dose.
- DONT crush or chew the tablet unless instructed.
- DONT take with other cough/cold medicines without consulting your doctor.
- DONT stop taking abruptly if used for chronic conditions.
8. Toxicology & Storage
Overdose: Primarily due to Etofylline/Theophylline and Terbutaline components: Severe nausea/vomiting, agitation, tremors, tachycardia, cardiac arrhythmias (supraventricular and ventricular), hypotension or hypertension, seizures, hyperglycemia, hypokalemia, metabolic acidosis. In severe cases: Rhabdomyolysis, acute renal failure, respiratory arrest.
Storage: Store below 30°C, in a cool, dry place, protected from light and moisture. Keep out of reach of children.